Deciphering molecular complexity of HCV-associated lymphoproliferation.
B-cell monoclonality
HCV-associated lymphoproliferative disorders
direct-acting antivirals
molecular signatures
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
01
08
2023
accepted:
03
08
2023
medline:
5
10
2023
pubmed:
18
8
2023
entrez:
18
8
2023
Statut:
ppublish
Résumé
Recent clinical studies demonstrated the achievement of lymphoma responses in patients with Hepatitis C virus-associated indolent lymphoproliferative disorders (LPD) receiving direct-acting antivirals (DAAs) as their sole treatment. However, the molecular mechanisms underlying LPD responses to DAAs are still poorly understood. In their paper the authors provide new molecular insights on this issue, reporting intraclonal diversification and persistence of B-cell clones in most cases, despite viral eradication and beneficial clinical outcome. These provocative data suggest that the achievement of molecular response is probably not required for a 'functional cure' of these patients. Further comprehensive immunogenetic and mutational studies would be fundamental to dissect this biological puzzle and, ultimately, to refine improved treatment strategies in this setting. Commentary on: Mazzaro et al. Persistence of monoclonal B-cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus-associated lymphoproliferative disorders. Br J Haematol 2023;203:237-243.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
154-157Commentaires et corrections
Type : CommentOn
Informations de copyright
© 2023 British Society for Haematology and John Wiley & Sons Ltd.
Références
Defrancesco I, Zerbi C, Rattotti S, Merli M, Bruno R, Paulli M, et al. HCV infection and non-Hodgkin lymphomas: an evolving story. Clin Exp Med. 2020;20:321-328. https://doi.org/10.1007/s10238-020-00615-6
Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJM, Bernuzzi P, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25(7):1404-1410. https://doi.org/10.1093/annonc/mdu166
Frigeni M, Besson C, Visco C, Fontaine H, Goldaniga M, Visentini M, et al. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia. 2020;34(5):1462-1466. https://doi.org/10.1038/s41375-019-0687-2
Merli M, Rattotti S, Spina M, Re F, Motta M, Piazza F, et al. Direct-acting antivirals as primary treatment for hepatitis C virus-associated indolent non-Hodgkin lymphomas: the BArT study of the Fondazione Italiana Linfomi. J Clin Oncol. 2022;40(35):4060-4070. https://doi.org/10.1200/JCO.22.00668
Mazzaro C, Visentini M, Gragnani L, Vit F, Tissino E, Pozzo F, et al. Persistence of monoclonal B-cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus-associated lymphoproliferative disorders. Br J Haematol. 2023;203:237-243.
Merli M, Arcaini L. Management of marginal zone lymphomas. Hematology. 2022;2022(1):676-687. https://doi.org/10.1182/hematology.2022000362
Bertoni F, Conconi A, Capella C, Motta T, Giardini R, Ponzoni M, et al. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood. 2002;99(7):2541-2544. https://doi.org/10.1182/blood.v99.7.2541
Couronné L, Bachy E, Roulland S, Nadel B, Davi F, Armand M, et al. From hepatitis C virus infection to B-cell lymphoma. Ann Oncol off J Eur Soc Med Oncol. 2018;29(1):92-100. https://doi.org/10.1093/annonc/mdx635
Minafò YA, del Padre M, Cristofoletti C, Caprini E, Perez M, Aranburu A, et al. A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders. Genes Immun. 2020;21(2):131-135. https://doi.org/10.1038/s41435-020-0093-9
Defrancesco I, Visentini M, Zibellini S, Minafò YA, Rattotti S, Ferretti VV, et al. Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders. Am J Hematol. 2021;96(6):E210-E214. https://doi.org/10.1002/ajh.26167
Armand M, Degaud M, Tesson B, Laurent C, Vavasseur M, Parisot M, et al. Exploring the genetic landscape of HCV-related B-cell lymphomas using whole exome sequencing. Leukemia. 2023;37(6):1388-1391. https://doi.org/10.1038/s41375-023-01868-2